Wechselwirkungen · NovoNorm
NovoNorm 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-088405 · Präparat HOS-083643
In vitro data indicate that repaglinide is metabolised predominantly by CYP2C8, but also by CYP3A4. Clinical data in healthy volunteers support CYP2C8 as being the most important enzyme involved in repaglinide metabolism with CYP3A4 playing a minor role, but the relative contribution of CYP3A4 can be increased if CYP2C8 is inhibited. Consequently metabolism, and by that clearance of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 85318932acda2783c30565f489f51e291204476b1151e92e5c1df3ab1a6cf67d · Zeichen 158–543 im Abschnitt